Provided by Tiger Trade Technology Pte. Ltd.

Axsome Therapeutics

185.28
+2.061.12%
Volume:51.56K
Turnover:9.51M
Market Cap:9.34B
PE:-39.73
High:185.51
Open:183.09
Low:182.75
Close:183.22
52wk High:191.50
52wk Low:86.99
Shares:50.41M
Float Shares:41.87M
Volume Ratio:0.31
T/O Rate:0.12%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6630
EPS(LYR):-5.9944
ROE:-275.50%
ROA:-19.79%
PB:126.69
PE(LYR):-30.91

Loading ...

Auvelity Priority Review And Revenue Update Could Be A Game Changer For Axsome Therapeutics (AXSM)

Simply Wall St.
·
Feb 06

Axsome Therapeutics Is Maintained at Buy by Jefferies

Dow Jones
·
Feb 03

U.S. RESEARCH ROUNDUP-Adobe, Exxon Mobil, Stellar Bancorp

Reuters
·
Feb 03

Axsome Therapeutics CEO Herriot Tabuteau Reports Disposal of Common Shares

Reuters
·
Feb 03

Axsome Therapeutics AXS-05 Alzheimer's Launch Could Drive Upside, RBC Says

MT Newswires Live
·
Feb 03

Axsome Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jan 29

Axsome Therapeutics (AXSM) Valuation Check As Phase 3 AXS 14 Fibromyalgia Trial Gets Underway

Simply Wall St.
·
Jan 28

U.S. RESEARCH ROUNDUP- Boeing, Carvana, UnitedHealth

Reuters
·
Jan 28

Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23

GlobeNewswire
·
Jan 27

Axsome Therapeutics Chief Commercial Officer Ari Maizel Reports Disposal of Common Shares

Reuters
·
Jan 24

Axsome Therapeutics (AXSM) Is Up 7.4% After Advancing AXS-14 Into Phase 3 FORWARD Fibromyalgia Trial

Simply Wall St.
·
Jan 23

Axsome Therapeutics Is Maintained at Outperform by RBC Capital

Dow Jones
·
Jan 21

Axsome Therapeutics management to meet with Oppenheimer

TIPRANKS
·
Jan 21

RBC Raises Price Target on Axsome Therapeutics to $219 From $212, Keeps Outperform Rating

MT Newswires Live
·
Jan 21

Axsome Therapeutics price target raised to $219 from $212 at RBC Capital

TIPRANKS
·
Jan 21

Axsome Therapeutics Inc : RBC Raises Target Price to $219 From $212

THOMSON REUTERS
·
Jan 21

U.S. RESEARCH ROUNDUP-IBM, KLA, WEX

Reuters
·
Jan 21

Axsome Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Jan 20

Reaffirming Axsome Therapeutics as a Buy on Robust Commercial Growth and Advancing Late‑Stage Pipeline, With a Raised $260 Price Target

TIPRANKS
·
Jan 20

Axsome Therapeutics Is Maintained at Overweight by Piper Sandler

Dow Jones
·
Jan 17